Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 11/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 10/20 | 0.39 |
| ▸ | HTR2A | P28223 | 7/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1798792 | 0.76 | HTR2C (0.46) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL28789747 | 0.76 | KDM4E (0.44) | IRAK4PARP1KDM4EALDH1A1MAPT | |
| SCHEMBL18016883 | 0.73 | HTR2C (0.60) | HTR2CHTR2BHTR2ASLC6A4 | |
| SCHEMBL8628022 | 0.73 | KDM4E (0.44) | IRAK4KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL1116597 | 0.73 | KDM4E (0.44) | IRAK4KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL30646221 | 0.72 | KDM4E (0.47) | PARP1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL9442852 | 0.71 | OPRM1 (0.42) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL13742609 | 0.71 | HTR2C (0.57) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| SCHEMBL18016881 | 0.71 | HTR2C (0.65) | HTR2CHTR2BHTR2A | |
| SCHEMBL29818204 | 0.70 | SLC9A1 (0.45) | HTR2CKDM4EALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197925-A1 | O-CYCLOPROPYL-CARBOXANILIDES AND THEIR USE | SYNGENTA CROP PROTECTION, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| EP-1829865-A2 | Chemical compounds | Syngeta Participations AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| EP-1480955-B1 | O-CYCLOPROPYL-CARBOXANILIDES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2007-06-27 | — | — | EP | disclosed |
| US-20050221989-A1 | O-cyclopropyl-carboxanilides and their use as fungicides | SYNGENTA CROP PROTECTION, INC. | 2005-10-06 | — | — | US | disclosed |
| EP-1480955-A1 | O-CYCLOPROPYL-CARBOXANILIDES AND THEIR USE AS FUNGICIDES | Syngenta Participations AG (CH) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074491-A1 | O-CYCLOPROPYL-CARBOXANILIDES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050221989-A1 | O-cyclopropyl-carboxanilides and their use as fungicides | CBR3, CBR1, CYP2E1 | HTT 925/4885HTR2C 844/4885IRAK4 4337/4885 |
| US-20090197925-A1 | O-CYCLOPROPYL-CARBOXANILIDES AND THEIR USE | CBR3, CBR1, CYC1 | HTT 1035/4885HTR2C 971/4885IRAK4 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.